Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
The company takes another project from Taris into phase 3 as it chases a $5bn market.
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.